NCT05108038

A Study to Evaluate the PK, PD and Safety of CKD-382 in Healthy Subjects

A Randomized, Open-label, Crossover Phase 1 Clinical Trial to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety After Single/Multiple Administration of CKD-382, D860 and D027 in Healthy Subjects

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 42 (estimated)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 50 Years
• Healthy volunteers: Accepted

Summary

to evaluate the pharmacokinetics, pharmacodynamics and safety after single/multiple administration of CKD-382, D860 and D027 in healthy subjects

Detailed description

A randomized, open-label, crossover phase 1 clinical trial to evaluate the pharmacokinetics, pharmacodynamics and safety after single/multiple administration of CKD-382, D860 and D027 in healthy subjects

Conditions

• GERD

Interventions

Type	Name	Description
DRUG	CKD-382, D860, D027	QD, PO for 7days

Timeline

• Start date: 2021-10-07
• Primary completion: 2022-02-01
• Completion: 2022-02-01
• First posted: 2021-11-04
• Last updated: 2021-11-04

Locations

1 site across 1 country: South Korea